tirzepatide no bmi required Guidelines for Eligibility Tirzepatide for weight loss eligibility

Over 8 weeks, mean body weight in this cohort (50 adults) decreased from 73.69 7.73 kg at baseline to 67.36 7.87 kg at Week 8 (mean reduction: 6.33 kg

Patients should be instructed to rotate injection sites to minimize the risk of injection site reactions and to avoid injecting into areas that are tender, bruised, red, or hard

IV injections are typically done weekly in a 1ml to 4 ml volume and bring therapeutic levels within 24 hours

More serious risks, including pancreatitis, gallbladder complications, and thyroid-related contraindications, are reviewed with you before treatment begins and are part of what your monitoring visits watch for

Ongoing Support: Our team is here to offer continuous encouragement, guidance, and resources to keep you on track